Maitri Enterprises Ltd
Incorporated in 1991, Maitri Enterprises Ltd is engaged in the business of Pharmaceutical products
- Market Cap ₹ 10.9 Cr.
- Current Price ₹ 24.8
- High / Low ₹ 51.3 / 18.7
- Stock P/E 11.3
- Book Value ₹ 10.7
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 20.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Debtor days have improved from 148 to 68.9 days.
- Company's working capital requirements have reduced from 172 days to 89.3 days
Cons
- Company has a low return on equity of 3.56% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
4.55 | 19.92 | 13.26 | 18.93 | 28.66 | |
4.47 | 19.23 | 12.76 | 18.68 | 26.49 | |
Operating Profit | 0.08 | 0.69 | 0.50 | 0.25 | 2.17 |
OPM % | 1.76% | 3.46% | 3.77% | 1.32% | 7.57% |
0.09 | 0.06 | 0.11 | 0.13 | -1.00 | |
Interest | 0.02 | 0.32 | 0.37 | 0.73 | 0.77 |
Depreciation | 0.05 | 0.09 | 0.07 | 0.06 | 0.07 |
Profit before tax | 0.10 | 0.34 | 0.17 | -0.41 | 0.33 |
Tax % | 40.00% | 32.35% | 94.12% | 9.76% | 48.48% |
0.07 | 0.23 | 0.00 | -0.45 | 0.17 | |
EPS in Rs | 0.37 | 0.52 | 0.00 | -1.02 | 0.39 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
TTM: | 51% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 61% |
TTM: | 313% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | % |
3 Years: | -16% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 4% |
Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 4.40 | 4.40 | 4.40 | 4.40 | |
Reserves | 0.57 | 0.57 | 0.12 | 0.30 | |
5.72 | 6.34 | 10.54 | 6.89 | ||
6.85 | 7.09 | 6.61 | 4.77 | ||
Total Liabilities | 17.54 | 18.40 | 21.67 | 16.36 | |
0.28 | 0.24 | 0.24 | 0.24 | ||
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | |
Investments | 0.27 | 0.27 | 3.92 | 3.74 | |
16.99 | 17.89 | 17.51 | 12.38 | ||
Total Assets | 17.54 | 18.40 | 21.67 | 16.36 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-0.39 | 0.02 | 0.06 | 3.04 | ||
-3.27 | -0.24 | -3.45 | 1.23 | ||
3.69 | 0.24 | 3.49 | -4.40 | ||
Net Cash Flow | 0.03 | 0.02 | 0.10 | -0.12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 163.81 | 205.62 | 168.71 | 68.90 | |
Inventory Days | 210.48 | 261.85 | 150.06 | 102.82 | |
Days Payable | 186.79 | 206.97 | 122.82 | 78.06 | |
Cash Conversion Cycle | 187.50 | 260.50 | 195.96 | 93.66 | |
Working Capital Days | 157.76 | 248.29 | 177.20 | 89.28 | |
ROCE % | 4.91% | 2.43% | 16.06% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Audited Financial Results are published in two newspaper namely; 1. Free Press in English Edition 2. Lokmitra in Gujarati Language.
- Audited (Standalone And Consolidated) Financial Results For The Quarter And Year Ended On March 31, 2025 30 May
- Audited (Standalone And Consolidated) Financial Results For The Quarter And Year Ended On March 31, 2025 30 May
-
Board Meeting Outcome for Outcome Of 2Nd (02/2025-26) Board Meeting Of The Board
30 May - Approved audited standalone and consolidated financial results for FY ended March 31, 2025.
-
Board Meeting Intimation for Consideration And Approval Of The Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2025 And To Consider Other Business Items, If Any
20 May - Board meeting on May 30 to approve audited Q4 and annual results for FY 2024-25.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
a) Trading of Pharmaceutical & Medical Goods
b) Manufacturing of metal furniture
c) Trading of building materials